ugefuk.wordpress.com
An Abbott spokesman said the companywill Horsham, Pa.-based Centocor, a division of makes the blockbuster rheumatoid arthritis treatment and had sued Abbott over Abbott’s arthritid drug, Humira. Both are so-called anti-TNF arthritisd treatments. Horsham, Pa.-based Centocor said it is the exclusiv e licensee ofthe patent, which is co-owneds by . Centocor Presidenf Kim Taylor said “thed jury recognized our valuableintellectual property, findintg our patent both valid and We will continue to assert intellectual property rights for our immunology therapies, as they offer significant advances in treatmentt for patients with a number of immune mediated inflammator diseases.
” Abbott spokesman Scott E. Stoffe said, “We are disappointed in this and we are confident in the meritse of our case and that we will prevailon “The evidence clearly established that Humira was the first of its fully-human anti-TNF antibody medicine,” Stoffel said. “JNJ’s anti-TN antibody medication, Remicade, is partially made from mousew DNA. JNJ did not launcn a fully-human product until April 2009. In only when Humira was nearing its approval in 2002 did JNJ amendf the patent at issue in this litigation to claim that it haddiscovered fully-humaj antibodies in 1994.
JNJ acknowledgedx at trial that it did not startg working ona fully-human antibody until 1997 two years after Abbott discovered Humira and one year after Abbottt filed its patent applications for
No comments:
Post a Comment